Harvard Bioscience Inc (NASDAQ:HBIO) currently has a daily average trading volume of 329.39K but it saw 289110 shares traded in last market. With a market cap of 17.10M USD, the company’s current market price of $0.39 came falling about -0.51 while comparing to the previous closing price of $0.39. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.40 and as low as $0.35. In the recent trading on the day, stock has struck highest price mark of $0.38 while lowest mark touched by it was $0.4.
Taking a look at 20-day trading activity of Harvard Bioscience Inc (HBIO) gives us an average price of $0.4915, while its current price level is -91.18% below from 52-week high level whereas it is 9.30% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.7768 while that of 200 days or SMA-200 reads an average of $2.0759. A closer look into the stock’s movement over the week reveals that its volatility is standing at 11.24% during that period while stretching the period over a month that increases to 13.78%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 27.50 which implies that the stock is in oversold territory.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Speculative Buy” on March 10, 2023 while assigning a price target range of $3-$4.
Over the week, HBIO’s stock price is moving 0.60% up while it is -43.65% when we observe its performance for the past one month. Year-to-date it is -81.61% down and over the past year, the stock is showing a downside performance of -90.72%.
The company is expected to be releasing its next quarterly report on 2025-Mar-11, for which analysts forecasted an EPS of -0.04 while estimate for next year EPS is 0.05. In next quarter, company is expected to be making quarterly sales of $21.4M as analysts are expecting the sales for current fiscal year at $88.55M and seeing the company making $96.15M in sales next year. Moreover, analysts are in estimates of $19.2M for current-quarter revenue.
Currently, Harvard Bioscience Inc’s total number of outstanding shares is 44.07M with 7.05% of that held by the insiders while 76.72% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -17.79% and return on equity (ROE) at -18.19%. It has a 5.17 of forward P/E ratio. Stock’s beta reads 1.50. Stock has a price to book (P/B) ratio of 0.27 while price to sale or P/S ratio amounts to 0.18. Its return on asset (ROA) is -9.40% on average.
